[PDF][PDF] B-cell depletion–a frontier in monoclonal antibodies for multiple sclerosis
PA Calabresi - N Engl J Med, 2017 - msnz.org.nz
Multiple sclerosis is a disabling autoimmune disease in which immune cells target central
nervous system (CNS) antigens, leading to demyelination, glial activation, and subsequent …
nervous system (CNS) antigens, leading to demyelination, glial activation, and subsequent …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
Ocrelizumab: a new milestone in multiple sclerosis therapy
P Mulero, L Midaglia… - Therapeutic advances in …, 2018 - journals.sagepub.com
B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
D Jakimovski, B Weinstock-Guttman… - Expert opinion on …, 2017 - Taylor & Francis
Introduction. Multiple sclerosis (MS) is the most common neurological disease responsible
for early disability in the young working population. In the last two decades, based on …
for early disability in the young working population. In the last two decades, based on …
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
PS Sorensen, M Blinkenberg - Therapeutic advances in …, 2016 - journals.sagepub.com
B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …
[HTML][HTML] B-cell depletion with rituximab in relapsing–remitting multiple sclerosis
Background There is increasing evidence that B lymphocytes are involved in the
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and …
Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …